PDE5A and pulmonary arterial hypertension: Vasodilator therapies, their duration of use, and associated cost were assessed by DU status including the use of CCB and iloprost in addition to certain endothelial receptor antagonists (ERAs) and phosphodiesterase-5 inhibitors (PDE5) which were prescribed as a PAH specific therapy for those who had a concurrent diagnosis of PAH.